Trial Review

Registering a new trial?

To achieve prospective registration, we recommend submitting your trial for registration at the same time as ethics submission.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT04333134




Registration number
NCT04333134
Ethics application status
Date submitted
1/04/2020
Date registered
3/04/2020
Date last updated
14/07/2022

Titles & IDs
Public title
A Trial of SHR3162 in Healthy Caucasian Volunteers
Scientific title
A Phase 1, Open-Label, Two-Center Study to Evaluate the Safety and Pharmacokinetics of Single-Dose Fluzoparib in Healthy
Secondary ID [1] 0 0
SHR3162-I-113
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Healthy Volunteers 0 0
Condition category
Condition code

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - SHR3162

Experimental: Dose level 1 - Will enroll a single cohort of 12 healthy Caucasian subjects with an approximately one-to-one ratio of male to female subjectssubjects can be enrolled and dosed simultaneously.


Treatment: Drugs: SHR3162
Fluzoparib, also known as SHR3162, is an inhibitor of human PARP
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Pharmacokinetic - Cmax
Timepoint [1] 0 0
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Primary outcome [2] 0 0
Pharmacokinetic - AUC8
Timepoint [2] 0 0
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Primary outcome [3] 0 0
Pharmacokinetic - Tmax
Timepoint [3] 0 0
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Primary outcome [4] 0 0
Pharmacokinetic - CL/F
Timepoint [4] 0 0
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Primary outcome [5] 0 0
Pharmacokinetic - Vz/F
Timepoint [5] 0 0
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Primary outcome [6] 0 0
Pharmacokinetic - t1/2
Timepoint [6] 0 0
Pre-dose, 0.25, 0.5, 1, 1.5, 2 , 3, 4, 6, 8, 10, 24, 48, and 72 hr post-dose
Secondary outcome [1] 0 0
Adverse events
Timepoint [1] 0 0
Screening up to study completion, approximately 5 weeks
Secondary outcome [2] 0 0
Laboratory results
Timepoint [2] 0 0
Screening up to study completion, approximately 5 weeks
Secondary outcome [3] 0 0
Vital signs
Timepoint [3] 0 0
Screening up to study completion, approximately 5 weeks
Secondary outcome [4] 0 0
Electrocardiogram
Timepoint [4] 0 0
Screening up to study completion, approximately 5 weeks

Eligibility
Key inclusion criteria
1. Healthy Caucasian subjects, male and female, 18 to 45 years of age, inclusive, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests;
2. Male body weight =50 kg, female body weight =45 kg, body mass index (BMI) between =18.0 and =29.0 kg/m2, inclusive;
3. Female subjects agree not to be pregnant or lactating from beginning of the study screening to 90 days after trial completion:

* A negative blood and urine pregnancy test for females of childbearing potential at Screening and at Check-in, respectively;
* Females of reproductive potential are willing and able to employ a highly effective method of birth control/contraception to prevent pregnancy; A highly effective method of contraception is defined as one that results in a low failure rate (ie, less than 1% per year), when used consistently and correctly. Females of non-childbearing potential will not be required to use contraception. Females of non-child bearing potential are defined as permanently sterile (eg, due to hysterectomy) or postmenopausal (defined as at least 12 months following cessation of menses without an alternative medical cause and serum FSH levels >25 IU/L).
4. Males agree to refrain from donating sperm and fathering a child during the study and for at least 90 days after fluzoparib administration; male participants must agree to remain abstinent or must ensure a condom is used for all sexual activity (with a male or female partner) for this same duration.
5. Able and willing to refrain from caffeine or caffeine-containing products, alcohol, fruit juices, and smoking/tobacco products from at least 48 hours prior to Check-In until the end of Safety Follow Up;
6. Able and willing to refrain from eating and drinking poppy seed-containing products and grapefruit-related citrus fruits (eg, Seville oranges, pomelos) within 7 days prior to dosing until after collection of the final PK blood sample (Day 4);
7. Able and willing to refrain from strenuous exercise (heavy lifting, weight training, calisthenics, aerobics) within 7 days prior to dosing until after collection of the final PK blood sample (Day 4);
8. Willing and able to comply with all scheduled visits, study procedures, and provides written informed consent.
Minimum age
18 Years
Maximum age
45 Years
Sex
Both males and females
Can healthy volunteers participate?
Yes
Key exclusion criteria
1. Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, neuropsychiatric disease, or any condition that may affect drug absorption, distribution, metabolism, and excretion;
2. Had a severe infection, trauma or major surgery within 4 weeks of screening and at Check-In; plan to have a surgery during the trial;
3. A past medical history of ECG abnormalities, documented cardiac arrhythmias, or cardiovascular disease; or QTcF interval >450 msec for males, >470 msec for females, or <300 msec;
4. Subject's systolic blood pressure (SBP) is >140 or <90 mmHg, diastolic blood pressure (DBP) is >90 or <50 mmHg, resting heart rate <40 or >100 bpm, and respiratory rate <10 or >20 breaths/min at Screening or Check-in after resting in a semi-supine position for 5 minutes. Vitals can be repeated twice (a minimum of 1 to 2 minutes apart) based on the investigator's judgment;
5. History of immunodeficiency including seropositivity for human immunodeficiency virus (HIV), or other acquired or congenital immune-deficient disease, or any active systemic viral infection requiring therapy (eg, hepatitis B or C);
6. Subject has a history of type 1 hypersensitivity to any medication;
7. Subject has evidence of substance abuse, a history of substance abuse, or is positive for drugs of abuse (eg, methamphetamines, opiates, methadone, cocaine, amphetamines, cannabinoids, tricyclic antidepressants, phencyclidine, barbiturates, benzodiazepines), or alcohol at Screening and Check-in (Day -1);
8. History of symptomatic hypoglycemia;
9. Subjects who smoke more than 5 cigarettes per day or will not refrain from smoking starting from at least 48 hours prior to screening and check-in on Day -1, and during the study;
10. History of regular alcohol consumption in the past 3 months exceeding an average weekly intake of 14 standard drinks; 1 drink=5 ounces [150 mL] of wine or 12 ounces [360 mL] of beer or 1.5 ounces [45 mL] of hard liquor;
11. Subject has used prescription medications within 14 days or, as per PI discretion, over-the-counter medications, dietary/nutritional supplements (except hormonal contraceptives, paracetamol under 2 grams/day, vitamin supplements) within 7 days or 5 half-lives prior to fluzoparib administration;
12. Treatment with an investigational drug within 3 months (or 5 half-lives, whichever is longer) of dosing;
13. Use of medications affecting liver metabolism within 1 month of screening;
14. Blood donation or loss of more than 200 mL of blood within 1 month of screening; or blood donation or loss of more than 400 mL of blood within 3 months of screening; or received blood within 8 weeks of screening;
15. Any other major illness/condition that, in the investigator's judgment, substantially increased the risk associated with the subject's participation in and completion of the study or could preclude the evaluation of the subject's response.

Study design
Purpose of the study
Treatment
Allocation to intervention
Not applicable
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 1
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Completed
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
17/04/2020
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
Actual
30/06/2020
Sample size
Target
Accrual to date
Final
12
Recruitment in Australia
Recruitment state(s)
NSW
Recruitment hospital [1] 0 0
Atridia Pty Limited - Sydney
Recruitment postcode(s) [1] 0 0
2000 - Sydney

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Atridia Pty Ltd.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The purpose of this study is to assess the safety and PK characteristics of a single oral dose of fluzoparib in healthy Caucasian and Chinese subjects
Trial website
https://clinicaltrials.gov/study/NCT04333134
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT04333134